Colossal Biosciences acquires pet cloning firm ViaGen Pets.

1 week ago7 min read1 comments

In a move that signals a significant consolidation within the nascent biotechnology cloning sector, Colossal Biosciences—the ambitious de-extinction startup—has strategically acquired ViaGen Pets and Equine, a leading firm in the commercial pet cloning arena. This acquisition, Colossal's first since its headline-grabbing launch in 2021, represents more than a simple corporate takeover; it is a deliberate fusion of commercial genetic application with frontier-level species resurrection ambitions.Colossal, headquartered in Texas and founded by tech entrepreneur Ben Lamm, has captivated both the scientific community and the public imagination with its controversial mission to 'de-extinct' species like the woolly mammoth and, more recently, the dodo, a venture that recently secured a staggering $120 million in investor funding. However, its claims, such as having 'brought back' dire wolves by editing the DNA of existing gray wolves, have been met with robust scientific skepticism, sparking intense ethical debates about whether this constitutes true de-extinction or merely sophisticated genetic modification.The acquisition of ViaGen, also a Texas-based entity founded in 2002, provides Colossal with an immediate and formidable operational backbone. ViaGen is not merely a service for grieving pet owners seeking to replicate a beloved dog or cat; it is a repository of critical, proven technologies.Perhaps the most pivotal asset transferred in this deal is ViaGen's exclusive licensing and access to the breakthrough cloning technologies pioneered by the Roslin Institute in Edinburgh, Scotland—the very institution that created Dolly the sheep, the world's first cloned mammal, in 1996. This access to foundational IP is a game-changer, providing Colossal with a validated technological stack that moves its de-extinction projects from theoretical models toward tangible, repeatable processes.As Dr. Shawn Walker, ViaGen's chief science officer and a renowned cloning expert, stated, the partnership allows for the application of their advanced cryopreservation and cloning techniques to the ambitious goals of species restoration.The strategic implications are profound. ViaGen will continue its commercial operations under existing leadership, generating revenue and real-world data, while simultaneously expanding its work on cloning endangered species.This creates a powerful feedback loop where profits and procedures from pet cloning can directly subsidize and inform the more complex, long-term de-extinction efforts. It also lends Colossal a veneer of practical legitimacy, anchoring its futuristic goals in a business with a proven, albeit niche, market.The human element further illustrates this bridge between commerce and conservation. The involvement of celebrity investors like retired NFL star Tom Brady, who publicly collaborated with Colossal to clone his family's dog, demonstrates the public relations potential.Brady's endorsement, connecting the emotional act of preserving a family pet with the grander mission of saving endangered species, perfectly encapsulates the narrative Colossal is building. Similarly, filmmaker Peter Jackson's statement that the combined companies 'give humanity a real shot at saving the planet's biodiversity' frames the acquisition not as a corporate maneuver, but as a pivotal moment for conservation.Yet, the path forward is fraught with technical and ethical landmines. Cloning remains an inefficient process with low success rates, and the challenges of gestating a de-extinct species—requiring either a closely related surrogate or an artificial womb—are monumental.Ethically, critics question the allocation of vast resources to resurrecting lost species when countless existing ones face imminent extinction due to habitat loss and climate change. Furthermore, the very definition of 'de-extinction' is contested; creating a hybrid animal with some ancient DNA is a far cry from restoring a complex species to its original ecological niche. This acquisition, therefore, is not just a business story but a critical inflection point in the CRISPR era, where the lines between science fiction, commercial venture, and genuine conservation are becoming increasingly and irrevocably blurred.

#featured

#de-extinction

#cloning

#Colossal Biosciences

#ViaGen Pets

#genetics

#species preservation

#biotechnology